4月28日,翰森制药发布年报,2024年录得收入122.61亿元,同比增长约21.3%;录得年内溢利约43.72亿元,同比增长约33.4%;基本每股盈利为0.74元/股,业绩增长主要得益于创新药及合作产品收入增加。2024年,翰森制药资产总额为316.58亿元,同比下降4.18%;负债总额为29.78亿元,同比下降约58.8%;权益总额为286.80亿元,同比增长约11.2%;资产负债率降至...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.